References of "LIFRANGE, Eric"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailMastectomie bilaterale prophylactique chez les patientes a tres haut risque de cancer mammaire: au-dela de la technique...
BLERET, Valerie ULg; Cusumano, P.; DEZFOULIAN, Bahram ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 250-3

Bilateral prophylactic mastectomy is the most efficient risk management strategy for women at very high risk for breast cancer. Different methods can be used. The implementation of such a strategy must ... [more ▼]

Bilateral prophylactic mastectomy is the most efficient risk management strategy for women at very high risk for breast cancer. Different methods can be used. The implementation of such a strategy must respond to the request of a well informed patient. [less ▲]

Detailed reference viewed: 123 (9 ULg)
Full Text
Peer Reviewed
See detailGanglion sentinelle et sentibras: pour un "staging" axillaire sur mesure
Cusumano, P.; BLERET, Valerie ULg; Nos, C. et al

in Revue Médicale de Liège (2011), 66(5-6), 336-40

The status of the axillary lymph nodes is one of the most important prognostic factors in women with early stage breast cancer. Histologic examination of removed lymph nodes is the most accurate method ... [more ▼]

The status of the axillary lymph nodes is one of the most important prognostic factors in women with early stage breast cancer. Histologic examination of removed lymph nodes is the most accurate method for assessing spread of disease to these nodes. Axillary lymph node dissection (ALND) remains the standard approach for women who have clinically palpable axillary nodes. The benefits of ALND include its impact on disease control (axillary recurrence and survival), its prognostic value, and its role in treatment selection. However, the anatomic disruption caused by ALND may result in lymphedema, nerve injury, and shoulder dysfunction, which compromise functionality and quality of life. For patients who have clinically negative axillary lymph nodes, sentinel lymph node (SLN) biopsy offers a less morbid method to determine if there are positive nodes, in which case axillary node dissection would be necessary. Patients who are SLN-positive should undergo complete ALND. Axillary reverse mapping (ARM) is a recent improvement of ALND which, like the biopsy of the GS, would reduce morbidity. [less ▲]

Detailed reference viewed: 152 (9 ULg)
Full Text
Peer Reviewed
See detailLe cancer du sein de la femme âgée
MARTIN, Marie; COLLIGNON, Joëlle ULg; RORIVE, Andrée ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 400-408

Detailed reference viewed: 51 (5 ULg)
Full Text
Peer Reviewed
See detailTraitements ciblés dans le cancer du sein
JERUSALEM, Guy ULg; COLLIGNON, Joëlle ULg; RORIVE, Andrée ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 379-384

Detailed reference viewed: 62 (10 ULg)
Full Text
Peer Reviewed
See detailPrise en charge et suivi d'une série consécutive de 411 patientes opérées pour cancer du sein
LIFRANGE, Eric ULg; ANDRE, Chantal ULg; BLERET, Valerie ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 329-335

Detailed reference viewed: 52 (7 ULg)
Full Text
Peer Reviewed
See detailChimiothérapie et cancer du sein
COLLIGNON, Joëlle ULg; RORIVE, Andrée ULg; MARTIN, M. et al

in Revue Médicale de Liège (2011), 66(5-6), 372-378

Detailed reference viewed: 78 (15 ULg)
Full Text
Peer Reviewed
See detailHormonothérapie du cancer du sein
LIFRANGE, Eric ULg; ANDRE, Chantal ULg; BLERET, Valerie ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 367-371

Detailed reference viewed: 124 (26 ULg)
Full Text
Peer Reviewed
See detailL'observance au traitement de longue durée : le cas particulier de l'hormonothérapie adjuvante du cancer du sein
Bleret, Valerie ULg; Collignon, Joëlle ULg; Coucke, Philippe ULg et al

in Revue Médicale de Liège (2010), 65(5-6), 405-408

L'objectif de l'hormonothérapie adjuvante dans le cancer du sein est d'atteindre en pratique quotidiennee, une efficacité comparable à celle obtenue au cours des études cliniques. Malgré l'efficacité ... [more ▼]

L'objectif de l'hormonothérapie adjuvante dans le cancer du sein est d'atteindre en pratique quotidiennee, une efficacité comparable à celle obtenue au cours des études cliniques. Malgré l'efficacité démontrée de l'hormonothérapie, la compliance constitue un défi majeur et un problème multidimensionnel. Une meilleure compréhension des raisons de cette non-compliance aiderait à mieux identifier les patientes à risque et à développer des interventions capables d'améliorer l'adhésion à l'hormonothérapie adjuvante.C'est dans ce but que nous avons entrepris une revue de la littérature des six dernières années (Pub Med 2003-2006). [less ▲]

Detailed reference viewed: 164 (27 ULg)
Full Text
Peer Reviewed
See detailANTICORPS MONOCLONAUX ET CANCER DU SEIN: Actualités thérapeutiques
Collignon, Joëlle ULg; Gennigens, Christine ULg; Rorive, Andrée ULg et al

in Revue Médicale de Liège (2009), 64(5-6), 279-83

About 9,500 new breast cancers are diagnosed in Belgium every year. Improvement of our knowledge of altered molecular events leading to the proliferation of tumor cells has resulted in the development of ... [more ▼]

About 9,500 new breast cancers are diagnosed in Belgium every year. Improvement of our knowledge of altered molecular events leading to the proliferation of tumor cells has resulted in the development of targeted therapies in subgroups of cancers. One of the first validation of targeted therapy is the anti-HER-2 monoclonal antibody trastuzumab (Herceptin) in patients with overexpression of human epidermal growth factor receptor type 2 (HER2) occurring in 20 to 25% of invasive breast carcinoma. Trastuzumab binds the extracellular juxtamembrane domain and is only active in tumor with HER2 gene amplification detected by fluorescence in situ hybridization (FISH). The results from randomized trials have rapidly lead to the approvement of the drug in the metastatic and then in the adjuvant setting. Another targeted therapy, also approved in the treatment of breast cancer, is the monoclonal antibody bevacizumab with an anti-VEGF (Vascular Endothelial Growth Factor) activity. We will review the benefit of these targeted therapies in breast cancer and their role in the treatment of breast cancer. [less ▲]

Detailed reference viewed: 436 (39 ULg)
Full Text
Peer Reviewed
See detailValidation de la technique de biopsie du ganglion sentinelle dans le cancer du sein
Bleret, Valerie ULg; Lifrange, Eric ULg; Ghuysen, Vincent ULg et al

in Revue Médicale de Liège (2008), 63(1), 37-42

PURPOSE: Assessment of our experience and validation of the sentinel lymph node biopsy technique in breast cancer stage T0-T2N0M0 surgery. METHODS: Identification and biopsy of the sentinel lymph node by ... [more ▼]

PURPOSE: Assessment of our experience and validation of the sentinel lymph node biopsy technique in breast cancer stage T0-T2N0M0 surgery. METHODS: Identification and biopsy of the sentinel lymph node by the radio colloid method in a consecutive series of 205 patients undergoing surgery for breast cancer stage T0-T2N0M0 between October 1998 and January 2007, initially in association with a complete axillary lymph node dissection (learning curve), later in an elective way. Prospective recording of the data and analysis with an average follow-up of 50 months (3 to 102 months). RESULTS: Biopsy rate of the sentinel lymph node of 90%, false negative rate of the method 2.5%, axillary recurrence rate 0%. CONCLUSION: We confirm in this series that the sentinel lymph node biopsy technique is a reliable approach in our experience for the evaluation of the axillary lymph node status in breast cancer stage T0-T2N0M0. [less ▲]

Detailed reference viewed: 13 (2 ULg)
Full Text
Peer Reviewed
See detailActualites therapeutiques en gynecologie: pathologies organiques
HERMAN, Philippe ULg; Lifrange, Eric ULg; Nisolle, Michelle ULg et al

in Revue Médicale de Liège (2007), 62(5-6, May-Jun), 414-22

Over the last ten years, progress in evidence-based medicine coupled with technological and surgical breakthroughs have deeply changed the management of our patients. Uterine bleeding is the first cause ... [more ▼]

Over the last ten years, progress in evidence-based medicine coupled with technological and surgical breakthroughs have deeply changed the management of our patients. Uterine bleeding is the first cause of gynaecological consultation and the intrauterine progestin delivery system as well as new hysteroscopic procedures have optimized the therapeutic approach to this problem. Introduction of magnetic resonance imaging and interventional procedures have improved breast disease diagnosis and management; likewise sentinel node localization, introduction of aromatase and growth factors inhibitors, new radiotherapy procedures and pharmacogenomics, have helped to ameliorate breast cancer treatment. Pelvic surgery has been switching more and more towards laparoscopic procedures not only in the field of benign lesions (eg endometriosis), of surgery of prolapse and incontinence with new prosthetic materials, but also for an improved management of gynaecological cancers. [less ▲]

Detailed reference viewed: 107 (6 ULg)
Full Text
Peer Reviewed
See detailDefining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer
BUDZAR, A.; CHLEBOWSKI, R.; CUZICK, J. et al

in Current Medical Research & Opinion (2006), 22

Detailed reference viewed: 12 (4 ULg)
Full Text
Peer Reviewed
See detailInteret et limites du depistage de masse du cancer du sein par mammographie seule (mammotest)
Lifrange, Eric ULg; Bleret, Valerie ULg; Desreux, Joëlle ULg et al

in Revue Médicale de Liège (2003), 58(5), 331-7

The literature on screening mammography provides ample opportunity for doubt (the sceptics) and dogma (the screening zealots), and can be interpreted to prove both benefit and harm. The benefit of ... [more ▼]

The literature on screening mammography provides ample opportunity for doubt (the sceptics) and dogma (the screening zealots), and can be interpreted to prove both benefit and harm. The benefit of mammography screening, if any, is modest and the balance between beneficial (potentially, a 20% relative reduction in breast cancer mortality with no significant benefit on all-cause mortality) and harmful (physical and psychological morbidity related to the 15-40% missed cancers and the 80-90% false-positive diagnoses) effects is still delicate. The mammogram alone is a modest weapon. Concurrent clinical breast examination is mandatory. Women that are concerned about breast cancer should be fully informed of the potential benefits and risks of screening mammography. These women should benefit from mammography with concurrent clinical breast examination, and possible whole-breast ultrasound in heterogeneously dense and extremely dense breast patterns. [less ▲]

Detailed reference viewed: 114 (14 ULg)
Full Text
Peer Reviewed
See detailHormonosubstitution postmenopausique et risque de cancer mammaire: une mise a jour
van den Brule, F.; Lifrange, Eric ULg; Pintiaux, Axelle ULg et al

in Revue Médicale de Liège (2003), 58(4), 254-60

Numerous studies have examined the risk of breast cancer in patients with postmenopausal hormone substitution. Most of these studies are retrospective, and a few recent studies are prospective. The ... [more ▼]

Numerous studies have examined the risk of breast cancer in patients with postmenopausal hormone substitution. Most of these studies are retrospective, and a few recent studies are prospective. The observed results present with weak variations from baseline and major heterogeneity. Some studies highlight a slightly increased relative risk of breast cancer. A reanalysis of 51 studies demonstrates a relative risk of 1.35 for developing breast cancer during hormone substitution, with a 2.3% increased risk per year of use. Recently, the results of the WHI study have shown a slight increase of some risks of disease, including breast cancer (relative risk, 1.26). These results have induced the interruption of one of the 3 arms of the study (that of the patients treated with an estrogen-progestin combination), and have provoked a new discussion about the benefits and risks associated with hormone substitution. These facts have been largely related and commented in the general press. In this article, we review the important studies concerning this topic. [less ▲]

Detailed reference viewed: 41 (4 ULg)
Full Text
Peer Reviewed
See detailTraitement hormonal apres cancer du sein. Oui ... ou non?
Foidart, Jean-Michel ULg; Desreux, Joëlle ULg; Lifrange, Eric ULg et al

in Revue Médicale de Liège (2003), 58(2), 77-82

Clinical and experimental studies indicate that combined unique conjugated estrogens and medroxyprogesterone acetate moderately increase the risk of breast cancer in postmenopausal women. Classically ... [more ▼]

Clinical and experimental studies indicate that combined unique conjugated estrogens and medroxyprogesterone acetate moderately increase the risk of breast cancer in postmenopausal women. Classically, hormone replacement therapy is contra-indicated in women with a past history of breast cancer due to the fear of recurrence. However, these postmenopausal patients complain about hot flushes and adjuvant hormonal therapies (such as aromatase inhibitors, SERMs and Tamoxifen...) aggravate their symptoms. Observational studies and their meta-analyses do not show a deleterious effect but rather a beneficial impact of hormone replacement therapy among women with a past history of breast cancer. We summarise all these studies and their biological, clinical and epidemiological interpretations. We conclude that short term hormone replacement therapy is safe among those women requesting a replacement therapy after complete information. It is however advisable to conclude definitely only when prospective randomised trials with estradiol or tibolone (a promising alternative) will be available. Such ongoing studies will allow to conclude definitely the possible benefits and risks of hormone replacement therapy among patients with a past history of breast cancer. [less ▲]

Detailed reference viewed: 120 (4 ULg)
Full Text
Peer Reviewed
See detailPercutaneous stereotactic en bloc excision of nonpalpable breast carcinoma: a step in the direction of supraconservative surgery
Lifrange, Eric ULg; Dondelinger, Robert ULg; Foidart, Jean-Michel ULg et al

in Breast (Edinburgh, Scotland ) (2002), 11(6), 501-508

Recently, the advanced breast biopsy instrumentation (ABBI) system has been introduced as an alternative to conventional breast biopsy techniques. This study was prospectively conducted to evaluate the ... [more ▼]

Recently, the advanced breast biopsy instrumentation (ABBI) system has been introduced as an alternative to conventional breast biopsy techniques. This study was prospectively conducted to evaluate the potential of the ABBI method in locoregional management of a consecutive series of patients with nonpalpable mammographically detected breast carcinomas. Sixty-one consecutive patients underwent an ABBI procedure as a first step before possible surgery for nonpalpable breast lesions that would in any case require complete excision. For the 27 patients in whom the ABBI biopsy revealed malignancy further surgery was recommended, including re-excision of the biopsy site and axillary dissection in cases of infiltrating carcinoma. We calculated the probabilities that the ABBI specimen would have tumor-free margins and that a definitely complete excision had been achieved as a function of the mammographic or pathological diameter of the cancer. For cancer with a pathological diameter less than 10 mm, measured on the ABBI specimen, the probability (92%) of obtaining complete resection was significantly better than for larger lesions (P = 0.01, Fisher's exact test). Although the therapeutic perspectives for the ABBI method are limited at present, we suggest that this approach is a first step in the direction of a surgical strategy that is better adapted to the pathological characteristics peculiar to these small tumors, whose incidence is increasing. (C) 2002 Elsevier Science Ltd. All rights reserved. [less ▲]

Detailed reference viewed: 61 (11 ULg)
Full Text
Peer Reviewed
See detailStereotactic breast biopsy with an 8-gauge, directional, vacuum-assisted probe: initial experience
Lifrange, Eric ULg; Dondelinger, Robert ULg; Quatresooz, Pascale ULg et al

in European Radiology (2002), 12(9), 2180-2187

This study was prospectively conducted to assess the feasibility, safety and accuracy of an 8-G directional vacuum-assisted biopsy (DVAB) probe in the diagnostic management of nonpalpable breast lesions ... [more ▼]

This study was prospectively conducted to assess the feasibility, safety and accuracy of an 8-G directional vacuum-assisted biopsy (DVAB) probe in the diagnostic management of nonpalpable breast lesions (NPBL). Of 170 planned procedures which were indicated for investigation of BI-RADS category-3 to category-5 lesions, 153 were performed in 138 consecutive patients. The probe was targeted by the stereotactic unit of a prone table (United States Surgical Corporation, Norwalk, Conn.; and Lorad, Danbury, Conn.). Four to 18 (mean 8) core specimens were obtained for each lesion. In case of complete removal of the lesion, a localizing clip was deployed at the biopsy site. Adequate material for histopathologic examination was obtained in all cases (100%). Four of 138 (3%) patients experienced mild hematomas. We observed 15 of 39 failures (38%) to place the localizing clips. Thirteen of 153 (8%) procedures were inconclusive and required reintervention. Following DVAB, 42 of 138 (30%) patients underwent surgery. Subject to incomplete follow-up of the entire cohort, we observed no false-positive and one false-negative diagnosis. These preliminary results suggest that DVAB using an 8-G probe are feasible, safe and accurate. In our experience, clip placement was problematic. It is probable that increasing the dimensions of DVAB will only be relevant in a limited number of clinical situations, primarily the desire to obtain complete radiologic resections of the target abnormality. [less ▲]

Detailed reference viewed: 25 (5 ULg)
Full Text
Peer Reviewed
See detailEn Bloc Excision of Nonpalpable Breast Lesions Using the Advanced Breast Biopsy Instrumentation System: An Alternative to Needle Guided Surgery?
Lifrange, Eric ULg; Dondelinger, R. F.; Fridman, Viviana ULg et al

in European Radiology (2001), 11(5), 796-801

This study was prospectively conducted to evaluate the clinical potential of the advanced breast biopsy instrumentation (ABBI) system as an alternative to needle localization and open surgery in the ... [more ▼]

This study was prospectively conducted to evaluate the clinical potential of the advanced breast biopsy instrumentation (ABBI) system as an alternative to needle localization and open surgery in the management of nonpalpable breast lesions (NPBL). One hundred and eighty-six consecutive patients were referred for management of NPBL. Thirty-six underwent an ABBI procedure, offered as a first step before possible surgery for lesions which would in any case have required complete excision. The 18 patients with a malignant ABBI biopsy underwent re-excision of the biopsy site and axillary dissection was carried out in cases of infiltrating carcinoma. The other 150 patients underwent image-guided needle biopsy. Following these procedures, 60/150 (40%) patients underwent needle-guided surgery. Finally, 96/186 (51%) patients required complete excision. A total of 43 benign lesions and 53 carcinomas were confirmed. Thirty-six out of 96 (38%) excisions were obtained with the ABBI system; 17/43 (40%) benign lesions and 11/53 (21%) carcinomas were completely removed with the ABBI system. Out of 9 malignant specimens with a pathological size less than 10 mm, 5/9 (55%) had tumor-free margins and in 8/9 (89%) no residual disease was found at re-excision. The preliminary results of this study suggest that, in selected cases, en bloc excision using the ABBI procedure could be an alternative to conventional surgery. [less ▲]

Detailed reference viewed: 6 (1 ULg)
Peer Reviewed
See detailLa chirurgie mammaire supraconservatrice
Lifrange, Eric ULg; Colin, Claude ULg

in Journal de Gynécologie, Obstétrique et Biologie de la Reproduction (2000), 29(3), 285-7

Currently, 30% of the breast biopsies are performed for patients with nonpalpable lesions. The surgical management of these lesions had to evolve to a better three-dimensional targeting and a reduction of ... [more ▼]

Currently, 30% of the breast biopsies are performed for patients with nonpalpable lesions. The surgical management of these lesions had to evolve to a better three-dimensional targeting and a reduction of the tissue traumatism. The ABBI procedure allows the percutaneous one bloc excision of suspicious mammographically detected lesions with a diameter of less than 2cm. We prospectively evaluated this procedure as a therapeutic tool. Of the 10 malignant lesions with a pathologic size <10mm, 9 (90%) were completely resected with the ABBI device (no residual disease at re-excision of the biopsy site). The results of this preliminary study suggest a potential therapeutic role of the ABBI procedure in the therapeutic arsenal against mammary lesions. [less ▲]

Detailed reference viewed: 8 (1 ULg)